Biotech giant Gilead Sciences, Inc. GILD is scheduled to report fourth-quarter and full-year 2024 results on Feb. 11, after ...

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Gilead Sciences Inc. hit a new 52-week high, surpassing its previous peak of $99.45, which the company achieved on February ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price ...

To list the 10 Best Wide Moat Stocks to Invest In, we scanned through VanEck Morningstar Wide Moat ETF and some online ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Neurocrine (NBIX – Research Report) yesterday and set a price target of $148.00.

With a market cap of $121,1 billion, Gilead Sciences, Inc. (GILD) is a leading biopharmaceutical company specializing in the ...

Co-founder Finny Kuruvilla manages the firm’s largest two funds — Eventide Gilead and Eventide Healthcare and Life Sciences — and remains the firm’s largest owner, though more than 20 of ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly effective medicine. However, Ben Hargreaves finds that the company’s ...